Natera Inc. (NTRA)
NASDAQ: NTRA
· Real-Time Price · USD
157.15
0.49 (0.31%)
At close: May 05, 2025, 3:59 PM
157.38
0.15%
After-hours: May 05, 2025, 07:35 PM EDT
0.31% (1D)
| Bid | 156.41 |
| Market Cap | 21.3B |
| Revenue (ttm) | 1.7B |
| Net Income (ttm) | -190.43M |
| EPS (ttm) | -1.54 |
| PE Ratio (ttm) | -102.04 |
| Forward PE | -219.75 |
| Analyst | Buy |
| Ask | 160 |
| Volume | 714,896 |
| Avg. Volume (20D) | 1,691,913 |
| Open | 156.15 |
| Previous Close | 156.66 |
| Day's Range | 155.53 - 159.05 |
| 52-Week Range | 92.14 - 183.00 |
| Beta | 1.80 |
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; a...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jul 1, 2015
Employees 4,424
Stock Exchange NASDAQ
Ticker Symbol NTRA
Website https://www.natera.com
Analyst Forecast
According to 17 analyst ratings, the average rating for NTRA stock is "Buy." The 12-month stock price forecast is $185, which is an increase of 17.73% from the latest price.
Stock ForecastsNext Earnings Release
Natera Inc. is scheduled to release its earnings on May 8, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 days ago
-2.56%
NTRA stock has given up its prior loss. Natera sha...
Unlock content with
Pro Subscription
5 days ago
-2.56%
Natera shares are trading lower. The company reported results from its DEFINE-HT clinical trial.
